|Bid||0.00 x 45900|
|Ask||5.00 x 27000|
|Day's Range||4.79 - 4.87|
|52 Week Range||4.50 - 7.57|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||10.64|
|Earnings Date||Jan 25, 2017 - Feb 1, 2017|
|Forward Dividend & Yield||0.16 (3.27%)|
|1y Target Est||6.05|
November 16, 2018 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi.
Campos Neto, Treasury director for the Americas at Banco Santander, will replace Ilan Goldfajn, according to a text message from incoming Finance Minister Paulo Guedes. The appointment needs to be approved by Congress.
“Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]
Rating Action: Moody's assigns provisional ratings to Guincho Finance Portuguese ABS Notes backed by NPLs to be issued by Hefesto, STC, S.A. Moody's has not assigned any ratings to E[25,000,000] Class J Asset-Backed Variable Return Notes due [November 2038] and E[3,100,000] Class R Notes due [November 2038].
The bank said that its chief administrative officer and chief auditor have begun leaves of absence from the bank and named new leaders for key parts of the company.
November 11, 2018 - New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions 2018. Praluent® (alirocumab) was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina (known as acute coronary syndrome, or ACS), and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C (low-density lipoprotein cholesterol) of 100 mg/dL or higher at baseline.
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial Praluent significantly reduced major adverse.
The government announcement was a response to the popular and political outrage that followed a court decision last night that home buyers should pay the tax. Prime Minister Pedro Sanchez said the government regrets the Supreme Court decision handed down late Tuesday, and that it will make banks pay the tax from the moment it publishes a decree on the matter. “Never again will Spaniards pay the tax,” Sanchez said at a news conference in Madrid on Wednesday.
November 6, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis.
BOSTON, Nov. 5, 2018 /PRNewswire/ -- Santander Bank today announced the opening of its first branch in the Flushing neighborhood of Queens, located on 136-11 Roosevelt Avenue. To commemorate the event, Santander leaders will join community partners at a grand opening celebration and ribbon cutting later today to officially open the branch. Santander will present checks totaling $52,000 to three community organizations – Renaissance Economic Development Corporation (REDC), Chinese American Planning and Flushing Development Center.
New Platform to Help Businesses Simplify and Digitize Payment Processing BOSTON , Nov. 5, 2018 /PRNewswire/ -- Santander Bank today unveiled Santander® Enterprise Payment Link (EPL), a robust, host-to-host ...
Bank investors seem to be spooked by Turkey, but they may be overreacting. That is one lesson you could draw from the share-price reactions to third-quarter results from two Spanish banks.
November 1, 2018 - Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules (DNL747 and DNL758) target a critical signaling protein known as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.
The bank, based in Madrid, said it had earnings of 13 cents per share. The financial holding company posted revenue of $13.63 billion in the period. Its revenue net of interest expense was $13.63 billion, ...
Shares of Banco Santander Brasil SA were down 6 percent in Wednesday afternoon trading after analysts said the bank's quarterly results showed some signs of weakness in the third-quarter in spite of a higher-than-expected profit. Fee income and net interest margin - the difference between what a bank pays to borrow money and what it charges customers for loans - dropped in the quarter, raising questions if this performance would be a trend for the coming quarters. Chief Financial Officer Angel Santodomingo added fuel to the fire, saying on Wednesday that competition would pressure the bank's net income margin over coming quarters.
By Helen Reid LONDON (Reuters) - European shares rallied on Wednesday as a tumultuous October drew to a close and strong results from L'Oreal, Sanofi and banks Standard Chartered and Santander soothed ...
Banco Santander Brasil SA beat analysts' third-quarter estimates for profit on Wednesday as the bank reported another quarter of strong loan book growth. Recurring net income at the Brazilian unit of Spain's Banco Santander SA (SAN .MC) came in at 3.108 billion reais ($841 million) in the third quarter, 2.85 percent above the Refinitiv average estimate from analysts and 20.2 percent above the same period a year earlier. The bank's loan book reached 380.7 billion reais, driven by individuals and small companies.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Seagate Technology PLC (NASDAQ: STX ) is cheap. He can see it trading higher, but he can't recommend it because there are other tech stocks ...
A strong performance in its Spanish domestic market and a solid underlying business in Brazil drove Banco Santander (SAN.MC) third-quarter net profit up 36 percent from a year earlier while the lender also managed to improve its solvency position. Shares in Santander, the euro zone's biggest bank by market value, rose 4 percent on Wednesday, against a 1.5 percent rise on the European STOXX banking index (.SX7P). Analysts welcomed the bank's results at home in Spain and solid underlying performing in Brazil, as well as a recovery in Britain and its capacity to improve its capital ratios.
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how Banco Santander SA’s (BME:SAN) Read More...
Key HighlightsA positive surprise was the building of capital with 31 basis points added to fully-loaded core equity Tier 1 in the quarter, taking the measure to 11.11 percent. The election of Jair Bolsonaro has raised hopes he’ll implement reforms that will boost Santander’s largest market, and the real has recently pared losses.The U.K. showed signs of stabilizing after a tough regulatory environment and uncertainty surrounding Brexit weighed on the business in prior quarters. Santander has had to invest money in projects such as ring-fencing, which obliges banks to separate investment arms from retail banking.
Banco Santander SA’s (SAN.MC) third-quarter net profit grew strongly from a year earlier, when it reported a number of one-off charges. Net profit for the period rose roughly 36% to 1.99 billion euros ($2.